SCHEMBL3783316

SCHEMBL3783316

CN1CC2C(CNCc3ccc(Cl)c(Cl)c3)C2C1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.51
WDR77 Q9BQA1 1/20 0.51
SIGMAR1 Q99720 8/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
TMEM97 Q5BJF2 1/20 0.42
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSHR P16473 1/20 0.40
P2RX7 Q99572 1/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
HRH4 Q9H3N8 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765926 0.88 SLC6A9 (0.47) PRMT5WDR77CYP1A2CYP2D6CYP2C9
SCHEMBL3783254 0.86 PRMT5 (0.49) PRMT5WDR77SIGMAR1CYP1A2CYP2D6
SCHEMBL3770111 0.82 CXCR4 (0.49) CYP1A2CYP2D6CYP2C19P2RX7SLC6A4
SCHEMBL3778327 0.81 CACNA1H (0.40) PRMT5WDR77P2RX7SLC6A2SLC6A4
SCHEMBL3771852 0.80 SLC6A9 (0.42) PRMT5WDR77CYP1A2CYP2D6CYP2C9
SCHEMBL5506772 0.79 PRMT5 (0.61) PRMT5WDR77CYP1A2CYP2D6CYP2C9
SCHEMBL3782176 0.76 TSHR (0.51) TSHRP2RX7
SCHEMBL3770883 0.75 PRMT5 (0.38) PRMT5WDR77SIGMAR1CYP1A2CYP2D6
SCHEMBL3773434 0.75 P2RX7 (0.48) CYP2D6P2RX7
SCHEMBL3783314 0.74 SMN1; SMN2 (0.57) TSHRP2RX7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 PRMT5 900/4885WDR77 1586/4885SIGMAR1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.